



PRESS RELEASE

FIDIA FARMACEUTICI STRENGTHENS ITS POSITION IN OPTHALMOLOGY AND CONTINUES ITS EXPANSION INTO FOREIGN MARKETS THROUGH DIRECT INVESTMENTS

The Italian company has announced two major investments in Spain with the acquisition of three ophthalmic products on the Spanish market from the multinational company Novartis, and the acquisition of the Spanish company Soluciones Bioregenerativas SL.

Abano Terme (PD), September 2nd 2019 - Fidia, an Italian multinational pharmaceutical company, has announced the acquisition of three products from Novartis Farma Spain, a subsidiary of Novartis Pharma AG, Basel, a world leader in eye care,. This operation is part of a process to strengthen the presence of Fidia in the national and international ophthalmology market, which started in 2017 with the acquisition of Sooft Italia.

The agreement provides for the transfer or licence of the Spanish [and Andorran] rights relating to the products in question from Novartis to Fidia, including the marketing authorisation and the management and distribution activities for the products themselves.

The three products are: an intraocular injectable solution based on acetylcholine; an ophthalmic ointment that combines chloramphenicol and dexamethasone, and eye drops and ointment containing dexamethasone. These products have a consolidated presence in the Spanish market.

This acquisition, which offers Fidia the opportunity to expand its range of products and treatments for eye diseases, falls within the international expansion and growth strategies of the group, and includes an area of particular interest for expansion through direct investments in the Spanish market. Likewise, the recent acquisition of the Spanish company Soluciones Bioregenerativas SL, based in Barcelona, which operates at international level through its proprietary trademark Proteal®, will enable Fidia to consolidate its know-how and global presence in the field of regenerative medicine, specifically in joint care and aesthetic medicine, areas in which Fidia has long been engaged in the continuous identification and offer of new solutions.

Fidia's international successful expansion has also involved the recent establishment of a new wholly-owned subsidiary in Egypt, one of the most important and promising markets in Africa.

*"This operation," said **Carlo Pizzocaro, President and CEO of Fidia Farmaceutici**, "offers Fidia the possibility to expand and strengthen its international position in ophthalmology, an area in which it is already recognized at a national level, supported not only by important acquisitions, but also by its know-how and leadership in the research, development, production and marketing of pharmaceutical products based on hyaluronic acid. With this acquisition, Fidia further reinforces its presence in Spain, where it has been operational since 2014 with its own subsidiary and achieved a leading market position for the treatment of osteoarticular diseases."*

About Fidia Farmaceutici

Privately held, fully integrated Italian multinational company, with R&D, manufacturing, marketing and sales capabilities. The Company was founded in 1946 and is headquartered in Abano Terme (a short distance from Venice). Fidia's overall objective is establishing its leadership, through an extensive product portfolio mainly based on hyaluronic acid (HA) in joint care, wound healing, ophthalmology, aesthetic and autologous biological therapy, thereby providing patients and healthcare professionals with a variety of treatment options, such as pharmaceutical products, medical devices and food supplements. Over 55 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of MW (over 700 patents). Manufacturing operations - located in Italy - are inspected and approved by major international health authorities, including the US and Korean FDA, the Brazilian ANVISA and G-MED Notified Body, and comply with the strictest international regulations and safety standards. Fidia extends its global reach through local partners in 100+ countries worldwide, as well as wholly-owned subsidiaries in USA, Germany, Spain, France, Russia, Czech Republic, Slovakia, Romania, Egypt and Middle East.

For more information about Fidia

www.fidiapharma.com

For more information, contact:

Weber Shandwick

Chiara Domizi

T. +39 02 57378309 - M. +39 342 7402510

E-mail: cdomizi@webershandwickitalia.it

Elisa Franchi

T. +39 02 57378304 - M. +39 335 7173967

E-mail: efranchi@webershandwickitalia.it